Observational study in Pediatric transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors at 9 institutions in 1 country.
John McAteerDivision of Infectious Diseases, Department of Pediatrics, Johns Hopkins Children's Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-8913-6219
Divya D KalluriDepartment of Surgery, The Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-8118-8591
Rivka R AbedonDepartment of Surgery, The Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-2270-1580
Caroline X QinDepartment of Surgery, The Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-3212-3569
Scott R AuerbachDivision of Cardiology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-2341-0913
Olga CharnayaDivision of Nephrology, Department of Pediatrics, Johns Hopkins Children's Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-1104-2882
Lara A Danziger-IsakovDivision of Infectious Diseases, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.ORCID 0000-0002-5691-5221
Noelle H EbelDivision of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Lucile Packard Children's Hospital Stanford, Stanford University School of Medicine, Palo Alto, California, USA.ORCID 0000-0003-4494-1729
Amy G FeldmanSection of Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, Children's Hospital Colorado, University of Colorado Denver School of Medicine, Aurora, Colorado, USA.ORCID 0000-0003-4021-5615
Evelyn K HsuDivision of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington, USA.ORCID 0000-0003-4359-7102
Saeed MohammadDivision of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0002-2950-2552
Emily R PeritoDivision of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of California San Francisco Benioff Children's Hospital, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0002-2911-9684
Ashley M ThomasSection of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins Children's Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Teresa P Y ChiangDepartment of Surgery, NYU Grossman School of Medicine, New York City, New York, USA.ORCID 0000-0003-0601-7420
Jacqueline M Garonzik-WangDivision of Transplant Surgery, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Milwaukee, Wisconsin, USA.ORCID 0000-0002-2789-7503
Dorry L SegevDepartment of Surgery, NYU Grossman School of Medicine, New York City, New York, USA.ORCID 0000-0002-1924-4801
William A WerbelDepartment of Surgery, The Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-2943-5895
Douglas B MogulSection of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Johns Hopkins Children's Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-6486-3302
Johns Hopkins University · USChildren's Hospital Colorado · USNew York University · USCincinnati Children's Hospital Medical Center · USLucile Packard Children's Hospital · USSeattle Children's Hospital · USUniversity of California, San Francisco · USUniversity of Wisconsin–Madison · USVanderbilt University Medical Center · US
Funding
Patient Oriented Research in Solid Organ TransplantationK24AI144954 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SEGEV, DORRY L. · 2020 to 2024
$956k
The Landscape of Serious Infections following Kidney Transplantation in People Living with HIVK23AI157893 · NIAID · JOHNS HOPKINS UNIVERSITY · PI WERBEL, WILLIAM · 2021 to 2025
$847k
Implementation of Eplet Mismatch Analysis in Pediatric Kidney TransplantationK08DK134762 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI Olga Charnaya · 2023 to 2026
backgroundAdolescent solid organ transplant recipients (aSOTRs) who received three doses of the COVID-19 mRNA vaccine experience high seroconversion rates and antibody persistence for up to 3 months. Long-term antibody durability beyond this timeframe following three doses of the SARS-CoV-2 mRNA vaccine remains unknown. We describe antibody responses 6 months following the third vaccine dose (D3) of the BNT162b2 mRNA vaccination among aSOTRs.
methodsParticipants in a multi-center, observational cohort who received the third dose of the vaccine were analyzed for antibodies to the SARS-CoV-2 spike protein receptor-binding domain (Roche Elecsys anti-SARS-CoV-2-S positive: ≥0.8, maximum: >2500 U/mL). Samples were collected at 1-, 3-, and 6-months post-D3. Participants were surveyed at each timepoint and at 12-months post-D3.
resultsAll 34 participants had positive anti-RBD antibody titers 6 months post-D3. Variations in titers occurred between 3 and 6 months post-D3, with 8/28 (29%) having decreased antibody levels at 6 months compared to 3 months and 2/28 (7%) reporting increased titers at 6 months. The remaining 18/28 (64%) had unchanged antibody titers compared to 3-month post-D3 levels. A total of 4/34 (12%) reported breakthrough infection within 6 months and 3/32 (9%) reported infection after 6-12 months following the third dose of the SARS-CoV-2 mRNA vaccine.
conclusionsThe results suggest that antibody durability persists up to 6 months following three doses of the SARS-CoV-2 mRNA in aSOTRs. Demography and transplant characteristics did not differ for those who experienced antibody weaning. Breakthrough infections did occur, reflecting immune-evasive nature of novel variants such as Omicron.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Anti-spike antibody durability after SARS-CoV-2 vaccination in adolescent solid organ transplant recipients. · full record | OpenQuestion